---
title: "Understanding the Market | RemeGen rises over 3% as self-developed RC148 achieves dual-pathway breakthrough; institutions optimistic about future clinical potential"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/270557703.md"
description: "REMEGEN rose over 3%, as of the time of writing, up 3.41%, priced at HKD 78.8, with a transaction volume of HKD 98.3812 million. In terms of news, Huaxi Securities' research report pointed out that according to REMEGEN's official public account, the company has independently developed the PD-1/VEGF bispecific antibody RC148, with clinical research data for first-line monotherapy and second-line combination therapy for non-small cell lung cancer in phases I/II published. The research data shows that both the RC148 monotherapy and combination therapy demonstrate outstanding clinical efficacy and controllable safety, achieving breakthroughs through dual pathways. The firm stated that based on the early data from the RC148-C001 study, by August 2025, the RC148 in combination with docetaxel for the treatment of locally advanced or metastatic non-small cell lung cancer with driver gene negativity that has failed PD-1/PD-L1 inhibitors and platinum-based chemotherapy (either in combination or sequentially) has obtained breakthrough therapy designation (BTD) in China. The company is currently actively advancing related clinical trials: according to the company's investor research minutes, the phase II clinical trial of RC148 in combination therapy for first-line non-small cell lung cancer has completed patient enrollment and plans to initiate phase III clinical research for combination therapy in non-small cell lung cancer, optimistic about the subsequent clinical potential"
datetime: "2025-12-23T02:05:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/270557703.md)
  - [en](https://longbridge.com/en/news/270557703.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/270557703.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/270557703.md) | [繁體中文](https://longbridge.com/zh-HK/news/270557703.md)


# Understanding the Market | RemeGen rises over 3% as self-developed RC148 achieves dual-pathway breakthrough; institutions optimistic about future clinical potential

According to the Zhitong Finance APP, RemeGen (09995) has risen over 3%, currently up 3.41% at HKD 78.8, with a trading volume of HKD 98.3812 million.

In terms of news, Huaxi Securities' research report pointed out that according to RemeGen's official public account, the clinical research data for the company's self-developed PD-1/VEGF bispecific antibody RC148 in first-line monotherapy and second-line combination therapy for non-small cell lung cancer in phases I/II has been released. The research data shows that both RC148 monotherapy and combination therapy demonstrate outstanding clinical efficacy and controllable safety, achieving breakthroughs through dual pathways.

The firm stated that based on the early data from the RC148-C001 study, by August 2025, the indication for RC148 in combination with docetaxel for locally advanced or metastatic non-small cell lung cancer that is driven gene-negative and has failed PD-1/PD-L1 inhibitors and platinum-based chemotherapy (either in combination or sequentially) has obtained breakthrough therapy designation (BTD) in China. The company is currently actively advancing related clinical trials: according to the company's investor research minutes, the Phase II clinical trial of RC148 in combination therapy for first-line non-small cell lung cancer has completed patient enrollment and plans to initiate a Phase III clinical study for combination therapy in non-small cell lung cancer, showing optimism for the subsequent clinical potential

### Related Stocks

- [RemeGen (688331.CN)](https://longbridge.com/en/quote/688331.CN.md)
- [REMEGEN (09995.HK)](https://longbridge.com/en/quote/09995.HK.md)

## Related News & Research

- [RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial](https://longbridge.com/en/news/281458440.md)
- [RemeGen Lifts Price Cap on Share Repurchase](https://longbridge.com/en/news/272783447.md)
- [Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe](https://longbridge.com/en/news/280997570.md)
- [Eli Lilly says Taltz and Zepbound met primary and all key secondary endpoints for statistical superiority to Taltz monotherapy at 36 weeks](https://longbridge.com/en/news/280886666.md)
- [BullFrog AI Signs Major AI Drug Discovery Partnership](https://longbridge.com/en/news/281092205.md)